1. Home
  2. MD vs SNDX Comparison

MD vs SNDX Comparison

Compare MD & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pediatrix Medical Group Inc.

MD

Pediatrix Medical Group Inc.

HOLD

Current Price

$20.38

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$24.33

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MD
SNDX
Founded
1979
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
MD
SNDX
Price
$20.38
$24.33
Analyst Decision
Hold
Strong Buy
Analyst Count
4
12
Target Price
$20.00
$84.17
AVG Volume (30 Days)
771.5K
1.3M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
263.03
11.56
EPS
1.94
N/A
Revenue
$1,913,849,000.00
$172,352,000.00
Revenue This Year
$3.72
$112.05
Revenue Next Year
$2.62
$51.24
P/E Ratio
$10.21
N/A
Revenue Growth
N/A
627.84
52 Week Low
$11.84
$8.59
52 Week High
$24.99
$25.44

Technical Indicators

Market Signals
Indicator
MD
SNDX
Relative Strength Index (RSI) 54.72 66.70
Support Level $16.08 $19.46
Resistance Level $21.98 $25.16
Average True Range (ATR) 0.70 1.09
MACD 0.12 0.09
Stochastic Oscillator 95.15 76.80

Price Performance

Historical Comparison
MD
SNDX

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: